Medtronic unveils acquisition firepower, BCI neurosurgery partnership and MiniMed Go™ FDA clearance
Medtronic executives said at a San Francisco conference they have firepower to pursue multiple acquisitions to expand its portfolio. The company partnered with Precision Neuroscience on a Layer 7 cortical interface–StealthStation integration and gained FDA 510(k) clearance for its MiniMed Go™ Smart MDI system with InPen and Abbott’s Instinct sensor.
1. Medtronic Signals Robust M&A Capacity
At the JP Morgan Healthcare Conference in San Francisco on January 12, 2026, Medtronic executives disclosed that the company holds more than $20 billion of available cash and undrawn debt capacity earmarked for strategic acquisitions. This ‘‘significant firepower’’ position reflects the company’s disciplined capital allocation strategy, which has delivered compound annual revenue growth of 5 percent over the past three years and free cash flow margins near 20 percent. Medtronic’s leadership indicated that target areas include emerging robotics platforms and neurovascular devices, where the company has already completed six bolt-on deals since 2023 totaling over $3 billion in aggregate transaction value.
2. Strategic Partnership with Precision Neuroscience Enhances OR Capabilities
On January 12, 2026, Medtronic and Precision Neuroscience announced a co-development agreement to integrate Precision’s Layer 7™ cortical brain–computer interface with Medtronic’s StealthStation™ surgical navigation system. The combined solution will deliver high-resolution functional mapping data alongside 3D structural guidance in real time, reducing intraoperative decision-making time by up to 25 percent in early feasibility pilot studies. Medtronic’s Cranial & Spinal Technologies business, which generated $1.4 billion in revenues in fiscal 2025, will spearhead global distribution once the integrated platform completes a pivotal clinical trial slated to enroll 120 patients across five leading neurosurgical centers in North America and Europe.
3. FDA Clears MiniMed Go™ Smart MDI System
Medtronic Diabetes secured FDA 510(k) clearance on January 12, 2026 for its MiniMed Go™ Smart MDI system, combining the InPen™ smart insulin pen with Abbott’s Instinct continuous glucose sensor in a single mobile app. Clinical data from 1,852 Type 1 users of the previous-generation Smart MDI system showed Time in Range improvements from 55.7 percent to 71.5 percent when users responded to high-glucose alerts within one hour. The new system will address more than 15 million MDI patients in the U.S. and Europe, and commercial launch is planned for spring 2026, leveraging Medtronic’s established diabetes sales force covering 20,000 clinics worldwide.